2026-06-04 14:42:55
Latest Post
Alembic Pharmaceuticals Appoints Mr. Ramesh Juneja as Executive Vice President - Human Health (Sales and Marketing), India Business
Second Half Recovery Limits Nifty Losses to 78 Points; IT Index Tanks 5.5%
Akums Receives European CEP Approval for Cefpodoxime Proxetil
Tunwal E-Motors Reports Strong FY26 Results; Revenue Surges 55% to ₹276.84 Crore
Sharika Enterprises Enters High-Growth SCADA-ADMS Market with Uttarakhand Grid Modernization Project
Stock Report
Alkem Laboratories becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350
Posted On : 2026-06-03 20:37:03( TIMEZONE : IST )
Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM, "Alkem" and its subsidiaries) today announced the launch of semaglutide in single-shot pre-filled syringes in multiple dose strengths at price starting INR350.
Alkem is the first company in India to introduce semaglutide in single-shot pre-filled syringe format, expanding treatment options for patients and lowering entry barriers with its affordable pricing. The ready-to-use single shot pre-filled syringe format offers enhanced access, and convenience.
The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.
In March 2026, Alkem had already launched semaglutide in pre-filled disposable and reusable injection pens format in the Indian market. The company has also received regulatory approval for semaglutide vials, which will be launched soon.
Commenting on the development, Dr. Vikas Gupta, Chief Executive Officer, Alkem said, "Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced. In India, where we are seeing a continuous rise in disease burden, offering multiple, practical drug delivery formats is an important step in helping more patients start and stay on the therapy."
Alkem remains committed to advancing high-quality, affordable medicines across key therapeutic areas and supporting better patient care in India.
Shares of Alkem Laboratories Limited was last trading in BSE at Rs. 5276.55 as compared to the previous close of Rs. 5239.10. The total number of shares traded during the day was 10892 in over 3411 trades.
The stock hit an intraday high of Rs. 5293.00 and intraday low of 5164.00. The net turnover during the day was Rs. 57039774.00.
